Xencor Presents Phase 1 Dose-Selection Data for XmAb819
Xencor announced updated results from the Phase 1 study of its XmAb819 bispecific antibody in patients with advanced clear-cell renal cell carcinoma and ENPP3-positive tumors.
Story updates
08:35:41 AM UTC
SquawkNews
Xencor selected 400 mcg/kg IV as the proposed Phase 3 dose for XmAb819 after Phase 1 data showed 45.5% confirmed ORR (n=11) and a 6—month PFS estimate of 82% in ccRCC; a randomized trial vs tivozanib is planned, with potential registration-enabling study by end of 2027.Material DetailsContext by AI…